Compare Stocks: TVGN, PRQR, DTIL, and TNXP

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DTIL Precision BioSciences	$6.31 -0.3%	$7.28	$3.53 ▼ $9.62	$174.17M	1.27	243,111 shs	292,952 shs
PRQR ProQR Therapeutics	$1.64 +0.3%	$1.94	$1.33 ▼ $3.10	$172.27M	0.2	630,200 shs	622,637 shs
TNXP Tonix Pharmaceuticals	$8.91 -3.5%	$11.72	$8.69 ▼ $25.40	$152.82M	1.78	417,554 shs	802,578 shs
TVGN Tevogen Bio	$6.98 +3.9%	$6.95	$3.64 ▼ $39.50	$45.45M	0.19	8,360 shs	1,618 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DTIL Precision BioSciences	0.00%	+1.45%	-14.38%	-22.86%	+15.99%
PRQR ProQR Therapeutics	0.00%	-0.91%	-21.77%	-9.67%	-24.31%
TNXP Tonix Pharmaceuticals	0.00%	-9.63%	-33.36%	-27.80%	-62.80%
TVGN Tevogen Bio	0.00%	-6.62%	-2.65%	+20.97%	-82.48%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DTIL Precision BioSciences	$6.31 -0.3%	$7.28	$3.53 ▼ $9.62	$174.17M	1.27	243,111 shs	292,952 shs
PRQR ProQR Therapeutics	$1.64 +0.3%	$1.94	$1.33 ▼ $3.10	$172.27M	0.2	630,200 shs	622,637 shs
TNXP Tonix Pharmaceuticals	$8.91 -3.5%	$11.72	$8.69 ▼ $25.40	$152.82M	1.78	417,554 shs	802,578 shs
TVGN Tevogen Bio	$6.98 +3.9%	$6.95	$3.64 ▼ $39.50	$45.45M	0.19	8,360 shs	1,618 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DTIL Precision BioSciences	0.00%	+1.45%	-14.38%	-22.86%	+15.99%
PRQR ProQR Therapeutics	0.00%	-0.91%	-21.77%	-9.67%	-24.31%
TNXP Tonix Pharmaceuticals	0.00%	-9.63%	-33.36%	-27.80%	-62.80%
TVGN Tevogen Bio	0.00%	-6.62%	-2.65%	+20.97%	-82.48%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DTIL Precision BioSciences	2.60	Moderate Buy	$32.25	411.09% Upside
PRQR ProQR Therapeutics	2.63	Moderate Buy	$7.60	364.83% Upside
TNXP Tonix Pharmaceuticals	3.00	Buy	$24.50	174.97% Upside
TVGN Tevogen Bio	1.50	Reduce	$100.00	1,332.66% Upside

Current Analyst Ratings Breakdown

Latest TVGN, PRQR, DTIL, and TNXP Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/1/2026	PRQR ProQR Therapeutics	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform
10/1/2026	PRQR ProQR Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$3.00
10/1/2026	PRQR ProQR Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$8.00
8/20/2026	PRQR ProQR Therapeutics	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$8.00
8/17/2026	PRQR ProQR Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/14/2026	PRQR ProQR Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/10/2026	TNXP Tonix Pharmaceuticals	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Strong-Buy	$27.00
8/5/2026	DTIL Precision BioSciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
8/3/2026	DTIL Precision BioSciences	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
7/28/2026	TNXP Tonix Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/17/2026	TVGN Tevogen Bio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)

(Data available from 10/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DTIL Precision BioSciences	$34.26M	5.08	N/A	N/A	$4.03 per share	1.57
PRQR ProQR Therapeutics	$17.99M	9.58	N/A	N/A	$0.53 per share	3.08
TNXP Tonix Pharmaceuticals	$29.10M	5.25	N/A	N/A	$19.17 per share	0.46
TVGN Tevogen Bio	N/A	N/A	N/A	N/A	($211.84) per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DTIL Precision BioSciences	-$45.72M	-$2.80	N/A	N/A	N/A	-96.73%	-72.52%	-32.25%	11/2/2026 (Estimated)
PRQR ProQR Therapeutics	-$47.73M	-$0.46	N/A	N/A	N/A	-223.51%	-73.83%	-35.14%	11/5/2026 (Estimated)
TNXP Tonix Pharmaceuticals	-$124.02M	-$12.94	N/A	N/A	N/A	-548.64%	-68.99%	-61.31%	11/9/2026 (Estimated)
TVGN Tevogen Bio	-$26.27M	-$4.63	N/A	N/A	N/A	N/A	N/A	-468.32%	11/13/2026 (Estimated)

Latest TVGN, PRQR, DTIL, and TNXP Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2026	Q2 2026	TVGN Tevogen Bio	-$2.53	-$1.52	+$1.01	-$1.52	N/A	N/A
8/13/2026	Q2 2026	PRQR ProQR Therapeutics	-$0.1303	-$0.0914	+$0.0389	-$0.09	$4.56 million	$10.00 million
8/10/2026	Q2 2026	TNXP Tonix Pharmaceuticals	-$2.64	-$2.44	+$0.20	-$2.44	$7.72 million	$13.54 million
8/6/2026	Q2 2026	DTIL Precision BioSciences	-$0.8040	-$1.26	-$0.4560	-$1.26	$0.74 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
DTIL Precision BioSciences	N/A	N/A	N/A	N/A	N/A
PRQR ProQR Therapeutics	N/A	N/A	N/A	N/A	N/A
TNXP Tonix Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
TVGN Tevogen Bio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DTIL Precision BioSciences	0.50	12.82	12.82
PRQR ProQR Therapeutics	N/A	3.49	3.49
TNXP Tonix Pharmaceuticals	N/A	6.61	6.46
TVGN Tevogen Bio	N/A	0.33	0.33

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DTIL Precision BioSciences	37.99%
PRQR ProQR Therapeutics	32.65%
TNXP Tonix Pharmaceuticals	82.26%
TVGN Tevogen Bio	N/A

Insider Ownership

Company	Insider Ownership
DTIL Precision BioSciences	2.70%
PRQR ProQR Therapeutics	8.40%
TNXP Tonix Pharmaceuticals	2.00%
TVGN Tevogen Bio	65.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DTIL Precision BioSciences	67	27.60 million	26.86 million	No Data
PRQR ProQR Therapeutics	166	105.36 million	96.51 million	Optionable
TNXP Tonix Pharmaceuticals	142	17.15 million	16.81 million	Not Optionable
TVGN Tevogen Bio	3	6.51 million	2.24 million	N/A

TVGN, PRQR, DTIL, and TNXP Headlines

Recent News About These Companies

Tevogen Regains Compliance with Nasdaq Global Market Continued Listing Requirements

September 30, 2026 | globenewswire.com

Tevogen Bio (NASDAQ:TVGN) Stock Price Up 5.1% - Time to Buy?

September 23, 2026 | americanbankingnews.com

Tevogen Bio Holdings Rebrands as Tevogen Inc.

July 30, 2026 | tipranks.com

Tevogen Bio Holdings Corporate Event Calendar | NASDAQ:TVGN

July 24, 2026 | benzinga.com

Tevogen Bio Announces 2026 Annual Meeting of Stockholders

July 13, 2026 | globenewswire.com

Tevogen Bio Inc: Tevogen Announces Formation of a Healthcare Services Initiative

June 10, 2026 | finanznachrichten.de

Tevogen Bio Holdings Inc. Announces William Keane as Interim Head of New Healthcare Services Initiative, Exploring MSO and CRO Acquisitions

June 9, 2026 | quiverquant.comQ

Tevogen Announces Formation of a Healthcare Services Initiative

June 9, 2026 | globenewswire.com

Tevogen Bio Inc: Tevogen Advances Strategic Acquisition Initiatives with Potential to Support Approximately $100 Million in Combined Annual Revenue

May 28, 2026 | finanznachrichten.de

Tevogen Advances Strategic Acquisition Initiatives with Potential to Support Approximately $100 ...

May 28, 2026 | enidnews.comE

Tevogen Advances Strategic Acquisition Initiatives with Potential to Support Approximately $100 Million in Combined Annual Revenue

May 28, 2026 | globenewswire.com

Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of a Management Services ...

May 21, 2026 | caledonianrecord.comC

Tevogen Bio Holdings Inc. Signs Non-Binding Letter of Intent to Explore Strategic Healthcare Transaction

May 21, 2026 | quiverquant.comQ

Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of a Management Services Organization

May 21, 2026 | globenewswire.com

Tevogen Bio Holdings Inc. Reports Significant Operational Improvements and Strategic Growth Initiatives

May 18, 2026 | quiverquant.comQ

Letter to Shareholders from CEO Dr. Ryan Saadi

May 18, 2026 | globenewswire.com

Tevogen Announces $3 Million Private Investment at $8 Per Share, a 14% Premium from Latest ...

May 12, 2026 | caledonianrecord.comC

Tevogen Bio Holdings Inc. Secures $3 Million PIPE Financing from The Patel Family, LLP

May 12, 2026 | quiverquant.comQ

Tevogen Announces $3 Million Private Investment at $8 Per Share, a 14% Premium from Latest Market Close

May 12, 2026 | globenewswire.com

Tevogen (TVGN) Soars 11% as Firm Gears Up for AI Training Commercialization

May 5, 2026 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

TVGN, PRQR, DTIL, and TNXP Company Descriptions

Precision BioSciences NASDAQ:DTIL

$6.31 -0.02 (-0.32%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$6.30 -0.01 (-0.24%)

As of 10/2/2026 07:30 PM Eastern

Precision BioSciences, Inc., an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA. In addition, it develops PBGENE-NVS for sickle cell disease/beta thalassemia for insertion; PBGENE-DMD (excision) for duchenne muscular dystrophy; PBGENE-LL2 (insertion), a liver directed target; PBGENE-LL3, a central nervous system directed target; and iECURE-OTC (insertion) for ornithine transcarbamylase deficiency. The company has license and collaboration agreement with Caribou Biosciences, Inc.; license agreement with TG Cell Therapy, Inc. to develop, manufacture, and commercialize azer-cel for autoimmune diseases and other indications outside of cancer; development and license agreement with Eli Lilly and Company for the research and development of potential in vivo therapies for genetic disorders; Cellectis S.A.; iECURE, Inc. to develop ARCUS-based gene-insertion therapies; Duke University; and Novartis Pharma AG to discover and develop in vivo gene editing products. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.

ProQR Therapeutics NASDAQ:PRQR

$1.64 +0.01 (+0.31%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$1.62 -0.01 (-0.61%)

As of 10/2/2026 07:30 PM Eastern

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1). It also develops various other early-stage research programs, including AX-1005 for undisclosed targets in CVDs; AX-2402, which focuses on Rett syndrome; AX-2911 for nonalcoholic steatohepatitis (NASH); AX-0601 for obesity and Type 2 diabetes; and AX-9115 for rare metabolic condition, as well as various other targets. In addition, the company develops Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center; Inserm Transfert SA; Ionis Pharmaceuticals, Inc.; Vico Therapeutics B.V.; University of Rochester; and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. The company was incorporated in 2012 and is headquartered in Leiden, the Netherlands.

Tonix Pharmaceuticals NASDAQ:TNXP

$8.91 -0.32 (-3.47%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$8.98 +0.07 (+0.84%)

As of 10/2/2026 07:57 PM Eastern

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults. Its portfolio focuses on central nervous system disorders, as well as rare disease, immunology, and infectious disease product candidates. The company's priority is to submit a New Drug Application (NDA) to the FDA for TNX-102 SL (cyclobenzaprine HCl sublingual tablet), which has completed two positive Phase 3 studies for the management of fibromyalgia. TNX-102 SL is also being developed to treat fibromyalgia-type Long COVID, a chronic post-acute COVID-19 condition. Its TNX-1300 (cocaine esterase) is a biologic designed to treat cocaine intoxication and has been granted breakthrough therapy designation by the FDA. The company's rare disease development portfolio comprises TNX-2900, an intranasal potentiated oxytocin for the treatment of Prader-Willi syndrome (PWS). Its immunology portfolio includes TNX-1500, which is a biologic to address organ transplant rejection and autoimmune diseases. The company's infectious disease pipeline includes TNX-801, a vaccine in development to prevent smallpox and mpox. TNX-801 also serves as the live virus vaccine platform or recombinant pox vaccine platform for other infectious diseases, including TNX-1800 and TNX-1850, in development as a vaccine to protect against COVID-19. Its infectious disease development portfolio also comprises TNX-3900, and TNX-4200 are orally available CD45 antagonists in preclinical development. Tonix Pharmaceuticals Holding Corp. has collaboration agreement with Bilthoven Biologicals to advance TNX-801 mpox vaccine candidate; and with X-Chem, Inc. to develop broad-spectrum antivirals. The company was founded in 2007 and is headquartered in Chatham, New Jersey.

Tevogen Bio NASDAQ:TVGN

$6.98 +0.26 (+3.87%)

Closing price 10/2/2026 03:59 PM Eastern

Extended Trading

$6.58 -0.41 (-5.80%)

As of 10/2/2026 07:30 PM Eastern

Tevogen Bio Holdings Inc. operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients. It is also developing TVGN 601 for treating multiple sclerosis; TVGN 930 for the treatment of Epstein-Barr virus associated lymphomas; TVGN 920 for treating cervical cancer; and TVGN 960 for the treatment of mouth and throat cancer. The company was founded in 2020 and is headquartered in Warren, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest TVGN, PRQR, DTIL, and TNXP Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest TVGN, PRQR, DTIL, and TNXP Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

TVGN, PRQR, DTIL, and TNXP Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

TVGN, PRQR, DTIL, and TNXP Company Descriptions

Precision BioSciences NASDAQ:DTIL

ProQR Therapeutics NASDAQ:PRQR

Tonix Pharmaceuticals NASDAQ:TNXP

Tevogen Bio NASDAQ:TVGN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest TVGN, PRQR, DTIL, and TNXP Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest TVGN, PRQR, DTIL, and TNXP Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

TVGN, PRQR, DTIL, and TNXP Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

TVGN, PRQR, DTIL, and TNXP Company Descriptions

Precision BioSciences NASDAQ:DTIL

ProQR Therapeutics NASDAQ:PRQR

Tonix Pharmaceuticals NASDAQ:TNXP

Tevogen Bio NASDAQ:TVGN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools